

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

(Under 37 CFR 1.97(b) or 1.97(c))

**RECEIVED**  
Docket No.  
RDID00111US

MAY 07 2001

TECH CENTER 1600/2900

In Re Application Of: Salvatore J. Salamone

MAY 04 2001

Serial No.  
09/712,525Filing Date  
November 14, 2000Examiner  
To Be AssignedGroup Art Unit  
1614

Title: IMMUNOASSAY FOR HIV PROTEASE INHIBITORS

Address to:

Assistant Commissioner for Patents  
Washington, D.C. 20231**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
2. a Notice of Allowance under 37 CFR 1.311,

whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

**OR**

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

RECEIVED

Docket No.

RDID00111US

MAY 07 2001

In Re Application Of: Salvatore J. Salamone

TECH CENTER 1600/2900

Serial No.

12,525

Filing Date

November 14, 2000

Examiner

To Be Assigned

Group Art Unit

1614

Title: IMMUNOASSAY FOR HIV PROTEASE INHIBITORS

## Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 02-2958 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

## Certificate of Transmission by Facsimile\*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_)


on \_\_\_\_\_  
(Date)

Signature

Typed or Printed Name of Person Signing Certificate

## Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on April 27, 2001 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.



Signature of Person Mailing Correspondence

Leah Robison

Typed or Printed Name of Person Mailing Correspondence

\*This certificate may only be used if paying by deposit account.



Dated: April 27, 2001

Marilyn L. Amick, Reg. No. 30,444  
Roche Diagnostics Corporation  
9115 Hague Road  
P.O. Box 50457  
Indianapolis, IN 46250  
Tel.: (317) 521-7561  
Fax: (317) 521-2883

CC:

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

RDID00111

Application Number

09/712,525

RECEIVED

Applicant(s)

Salvatore J. Salamone

Filing Date

November 14, 2000

Group A

MAY 07 2001  
1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

TECH CENTER 1600/2900

1 Jean-Marie Poirier, et al., "Simultaneous Determination of the Five HIV-Protease Inhibitors: Amprenavir, Indinavir, Nelfinavir, Ritonavir, and Saquinavir in Human Plasma by Solid-Phase Extraction and Column Liquid Chromatography" Therapeutic Drug Monitoring, Vol. 22, No. 4, pgs 465-473, 2000 Lippincott Williams & Wilkins, Inc., Philadelphia

2 Rory P. Remmel, et al., "Simultaneous HPLC Assay for Quantification of Indinavir, Nelfinavir, Ritonavir, and Saquinavir in Human Plasma", Clinical Chemistry 46:1 pgs 73-81

3 H.R. Wiltshire, et al., "Chromatographic and Immunochemical Approaches to the Analysis of the HIV Protease Inhibitor Saquinavir in Plasma" Analytical biochemistry 281, 105-114 (2000), doi: 10, 1006/abio.2000, 4545

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.